CHANGING THE WAY THE WORLD BREATHES AGM PRESENTATION NOVEMBER 30th 2015
This document contains certain forward-looking statements, relating to Rhinomed Limited’s (Rhinomed) business which can be identifjed by the use of forward looking terminology such as “promising,” “plans,” “anticipated,” “will,” “project,” “believe,” “forecast,” “expected,” “estimated,” “targeting,” “aiming,” “set to,” “potential,” “seeking to,” “goal,” “could provide,” “intends,” “is being developed,” “could be,” “on track,” or similar expressions or by express or implied discussions regarding potential fjlings or marketing approvals, or potential future sales of the company’s technologies and products. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially difgerent from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory fjlings will satisfy any specifjc health authority and other health authorities requirements regarding any one or more product or technology nor can there any assurance that such products or technologies will be approved by any health authorities for sale in any markets or that they will reach any particular level of sales. In particular, managements expectations regarding the approval and commercialization of the technology could be afgected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve signifjcant risks and uncertainties about our products, technology, fjnancial result, and business prospects. Should one of more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Rhinomed Is providing this information as of the date of this presentation and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. 2015
OUR MISSION RADICALLY IMPROVE THE WAY YOU BREATHE, SLEEP, MAINTAIN YOUR HEALTH, AND TAKE MEDICATION. 2015
SHAREHOLDER OVERVIEW Ordinary Fully Paid Shares 612,902,124 100% Top 20 Shareholders 182,658,953 29.80% Kroy Wren 50,000,000 8.15 HSBC Custodian Managers 14,819,427 2.41 ANALYST REPORTS Abingdon Nominees 14,000,000 2.28 Morgans - Scott Power Kensington Capital 13,500,000 2.20 Baillieus - Josh Kanakourakis Fifty Second Celebration PTY LTD 9,062,500 1.48 Bioshares - Mark Pacasz 2015
BOARD AND MANAGEMENT • A nasal and respiratory medical technology Our focus is on unmet needs in: company based in Melbourne, Australia • Sports & Exercise • Sleep (Snoring, Sleep Quality and Sleep Apnea) • Rhinomed develops, markets and partners its • Wellness internal nasal technology platform into multiple • Drug Delivery form factors – internal nasal devices Non Executive Chairman Mr. Martin Rogers CEO Mr. Michael Johnson Non Executive Director Mr. Brent Scrimshaw CFO/COO Ms. Justine Heath Non Executive Director Dr. Eric Knight Head Sales & Marketing Mr. Shane Duncan Executive Director Mr. Michael Johnson Head Sport Science Dr. Mitch Anderson Joint Company Secretary Mr. Phillip Hains UK Business Development Ms. Lesley Jarvis Joint Company Secretary Mr. Justyn Stedwell 2015
RHINOMED IS BECOMING A GLOBAL LEADER IN NASAL AND SLEEP TECHNOLOGY Technology Platform - 60 Patents+ (13 Granted) SLEEP OBSTRUCTIVE NASAL DRUG DISORDERED DYSPNEA WELLNESS SLEEP APNEA DELIVERY BREATHING AEROBIC INPEAP - MILD/ ACTIVITY: SNORING DECOGESTANT MIGRAINE MODERATE ACTIVE OBSTRUCTIVE SLEEP APNEA AEROBIC ACTIVITY: SLEEP QUALITY ANXIETY PAIN RELIEF MUTE+ - PASSIVE ADJUNCT TO MILD /MODERATE AND SEVERE APPETITE OBSTRUCTIVE NICOTINE SUPPRESSANT SLEEP APNEA 2015
2014-15: SUBSTANTIAL AND STRATEGICALLY IMPORTANT MILESTONES ACHIEVED 2014 2015 FEBRUARY Turbine 2.0 released JULY Turbine registered with US FDA APRIL Mute ranged by Symbion and Sigma AUGUST Chris Froome wears Turbine in Vuelta a Espana Australian pharmacy distribution begins APRIL - JUNE SEPTEMBER Rhinomed exhibits Turbine at Interbike (US) International Business Development program commences Rhinomed exhibits Mute at American Sleep OCT/NOV Turbine distribution grows to 14 countries JUNE Association conference INPEAP Obstructive Sleep Apnea trial commences at NOVEMBER Turbine redesign commences Monash Health Mute design finalized JULY Chris Froome joins as Global Ambassador for Turbine Chris Froome wins 2015 Tour de France INPEAP design program begins Shannon Rowbury breaks Mary Deckers 31 year old 1500m Mute User trial completed (n=236) – reports 75% reduction American record DECEMBER in snoring frequency and severity AUGUST Boots to distribute Mute exclusively in UK Mute successfully registered with USFDA SleepGP partnership educating GPs on role of snoring and sleep begins Mute successfully registered with Australian TGA Mute Snoregust campaign Mute awarded CE Mark SEPTEMBER Rhinomed exhibits at Interbike (US) Aerovelo set new world record for human powered speed Mute production program begins (139km/hr) Disposal of Vibrovein asset OCTOBER Linda Villumsen becomes new UCI world Time Trial champion NOVEMBER Internal launch of Mute at Boots HQ Nottingham Rhinomed exhibits at Australian Sleep Down Under conference Turbine goes in sale on Boots.com UK consumer launch of Mute 2015
PROVING COMMERCIAL AND STRATEGIC VALUE DEMONSTRATE VALUE IN HIGH DEMONSTRATE GROWTH MARKET PLATFORM BUILD OUT EXTENSIONS SECURE GLOBAL 4 DISTRIBUTION AND GENERATE EARLY FOOT PRINT 3 REVENUES 2 1 2015
PROVING COMMERCIAL AND STRATEGIC VALUE DEMONSTRATE & EXTEND DISTRIBUTION DEVELOP HIGH VALUE VALIDATE DEMAND STRATEGIC PROGRAMS • Expand global retail • Use Australia as a test distribution through Expand value of IP market strategic relationships portfolio through High value strategic • Target early adopters • Drive sustainable development programs: revenue through premium branding and • Decongestion - UK secure channels market (£243 million) • Obstructive Sleep Apnea Global Revenues - (US$15 billion+) • Global Drug Delivery Market US$41 Billion - Nasal Drug Delivery ($US9 billion) 2015
EARLY STAGE REVENUE GROWTH TURBINE ONLINE CUSTOMERS 4000 3500 3000 2500 2000 1500 1000 500 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2014 2015 2015
EARLY STAGE REVENUE GROWTH MUTE ONLINE CUSTOMERS 4000 3500 3000 2500 2000 1500 1000 500 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2014 2015 2015
EARLY STAGE REVENUE GROWTH MUTE TOTAL STORES 1000 900 800 700 600 500 400 300 200 100 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 2014 2015 AUSTRALIAN PHARMACY AUSTRALIAN CLINICS UK PHARMACY TOTAL MUTE STORES 2015
2015
TURBINE • Sports breathing technology that combats dyspnea (shortness of breath) and those suffering from nasal obstruction • Designed to helps athletes breathe easier during sport and aerobic exercise • Adoption from athletes in training, pre event preparation, competition and recovery • RRP US$27.95 • Approximately 10 uses per product (less than $1 a day) • Sold on line and through sporting goods stores 2015
TURBINE GROWING GLOBAL DISTRIBUTION FOOTPRINT 2015
TURBINE Matt Goss Professional Cyclist HOW IT WORKS Breathing with Turbine increases the effjciency of getting air into your lungs, which allows you to reach maximum potential. • Technology platform • Assists with mental proven to increase focus by providing airflow, on average by valuable biofeedback 38% about breathing nasally, a mechanism which also • Reduces the energy promotes nitric oxide exerted during breathing release to optimise ( by minimising blood flow in the lungs resistance at the nasal valve ) • May improve physical recovery by minimising • Maximises intake of the cost of breathing warm, filtered and and allowing efficient, humidified air relaxed breathing • May reduce breathing patterning difficulties related to obstructed nasal 2015
TURBINE - MEDIA COVERAGE 2 1 7 3 5 4 Turbine with Chris Froome 6 8 18 2015
DOES TURBINE HELP?
OVER THE LAST 12 MONTHS TURBINE HELPED TURBINE HELPED RACHEL NEYLAN LINDA VILLMUSEN WIN THE INAUGURAL BECOME THE 2015 UCI CADEL EVANS RIDE TIME TRIAL WORLD CHAMPION TURBINE HELPED TURBINE HELPED TEAM SHANNON ROWBURY AEROVELO SET A NEW SET A NEW AMERICAN WORLD RECORD FOR RECORD FOR THE HUMAN POWERED 1500 METERS SPEED - 139.5KM/HR 2015
TURBINE HELPED CHRIS FROOME WIN HIS SECOND TOUR DE FRANCE 2015
TURBINE PROVIDES THE ‘MARGINAL GAIN’ In the last year Turbine has helped people all over the world achieve new records and set new personal bests by making every breath count 2015
Recommend
More recommend
